PURPOSE: For patients with breast cancer (BC), the optimal time to initiation of adjuvant chemotherapy (TTC) after definitive surgery is unknown. We evaluated the association between TTC and survival according to breast cancer subtype and stage at diagnosis. PATIENTS AND METHODS: Women diagnosed with BC stages I to III between 1997 and 2011 who received adjuvant chemotherapy at our institution were included. Patients were categorized into three groups according to TTC: ≤ 30, 31 to 60, and ≥ 61 days. Survival outcomes were estimated and compared according to TTC and by BC subtype. RESULTS: Among the 6,827 patients included, the 5-year overall survival (OS), relapse-free survival (RFS), and distant RFS (DRFS) estimates were similar for the different TTC categories. Initiation of chemotherapy ≥ 61 days after surgery was associated with adverse outcomes among patients with stage II (DRFS: hazard ratio [HR], 1.20; 95% CI, 1.02 to 1.43) and stage III (OS: HR, 1.76; 95% CI, 1.26 to 2.46; RFS: HR, 1.34; 95% CI, 1.01 to 1.76; and DRFS: HR, 1.36; 95% CI, 1.02 to 1.80) BC. Patients with triple-negative BC (TNBC) tumors and those with human epidermal growth factor receptor 2 (HER2) -positive tumors treated with trastuzumab who started chemotherapy ≥ 61 days after surgery had worse survival (HR, 1.54; 95% CI, 1.09 to 2.18 and HR, 3.09; 95% CI, 1.49 to 6.39, respectively) compared with those who initiated treatment in the first 30 days after surgery. CONCLUSION: TTC influenced survival outcomes in the overall study cohort. This finding was particularly meaningful for patients with stage III BC, TNBC, and trastuzumab-treated HER2-positive tumors who experienced worse outcomes when chemotherapy was delayed. Our findings suggest that early initiation of chemotherapy should be granted for patients in these high-risk groups.
PURPOSE: For patients with breast cancer (BC), the optimal time to initiation of adjuvant chemotherapy (TTC) after definitive surgery is unknown. We evaluated the association between TTC and survival according to breast cancer subtype and stage at diagnosis. PATIENTS AND METHODS: Women diagnosed with BC stages I to III between 1997 and 2011 who received adjuvant chemotherapy at our institution were included. Patients were categorized into three groups according to TTC: ≤ 30, 31 to 60, and ≥ 61 days. Survival outcomes were estimated and compared according to TTC and by BC subtype. RESULTS: Among the 6,827 patients included, the 5-year overall survival (OS), relapse-free survival (RFS), and distant RFS (DRFS) estimates were similar for the different TTC categories. Initiation of chemotherapy ≥ 61 days after surgery was associated with adverse outcomes among patients with stage II (DRFS: hazard ratio [HR], 1.20; 95% CI, 1.02 to 1.43) and stage III (OS: HR, 1.76; 95% CI, 1.26 to 2.46; RFS: HR, 1.34; 95% CI, 1.01 to 1.76; and DRFS: HR, 1.36; 95% CI, 1.02 to 1.80) BC. Patients with triple-negative BC (TNBC) tumors and those with humanepidermal growth factor receptor 2 (HER2) -positive tumors treated with trastuzumab who started chemotherapy ≥ 61 days after surgery had worse survival (HR, 1.54; 95% CI, 1.09 to 2.18 and HR, 3.09; 95% CI, 1.49 to 6.39, respectively) compared with those who initiated treatment in the first 30 days after surgery. CONCLUSION: TTC influenced survival outcomes in the overall study cohort. This finding was particularly meaningful for patients with stage III BC, TNBC, and trastuzumab-treated HER2-positive tumors who experienced worse outcomes when chemotherapy was delayed. Our findings suggest that early initiation of chemotherapy should be granted for patients in these high-risk groups.
Authors: Carlos Jara Sánchez; Amparo Ruiz; Miguel Martín; Antonio Antón; Blanca Munárriz; Arrate Plazaola; José Schneider; Purificación Martínez del Prado; Emilio Alba; Antonio Fernández-Aramburo Journal: Breast Cancer Res Treat Date: 2006-07-06 Impact factor: 4.872
Authors: Donald A Berry; Constance Cirrincione; I Craig Henderson; Marc L Citron; Daniel R Budman; Lori J Goldstein; Silvana Martino; Edith A Perez; Hyman B Muss; Larry Norton; Clifford Hudis; Eric P Winer Journal: JAMA Date: 2006-04-12 Impact factor: 56.272
Authors: Kathleen I Pritchard; Lois E Shepherd; Frances P O'Malley; Irene L Andrulis; Dongsheng Tu; Vivien H Bramwell; Mark N Levine Journal: N Engl J Med Date: 2006-05-18 Impact factor: 91.245
Authors: Martine J Piccart-Gebhart; Marion Procter; Brian Leyland-Jones; Aron Goldhirsch; Michael Untch; Ian Smith; Luca Gianni; Jose Baselga; Richard Bell; Christian Jackisch; David Cameron; Mitch Dowsett; Carlos H Barrios; Günther Steger; Chiun-Shen Huang; Michael Andersson; Moshe Inbar; Mikhail Lichinitser; István Láng; Ulrike Nitz; Hiroji Iwata; Christoph Thomssen; Caroline Lohrisch; Thomas M Suter; Josef Rüschoff; Tamás Suto; Victoria Greatorex; Carol Ward; Carolyn Straehle; Eleanor McFadden; M Stella Dolci; Richard D Gelber Journal: N Engl J Med Date: 2005-10-20 Impact factor: 91.245
Authors: Edward H Romond; Edith A Perez; John Bryant; Vera J Suman; Charles E Geyer; Nancy E Davidson; Elizabeth Tan-Chiu; Silvana Martino; Soonmyung Paik; Peter A Kaufman; Sandra M Swain; Thomas M Pisansky; Louis Fehrenbacher; Leila A Kutteh; Victor G Vogel; Daniel W Visscher; Greg Yothers; Robert B Jenkins; Ann M Brown; Shaker R Dakhil; Eleftherios P Mamounas; Wilma L Lingle; Pamela M Klein; James N Ingle; Norman Wolmark Journal: N Engl J Med Date: 2005-10-20 Impact factor: 91.245
Authors: Heikki Joensuu; Pirkko-Liisa Kellokumpu-Lehtinen; Petri Bono; Tuomo Alanko; Vesa Kataja; Raija Asola; Tapio Utriainen; Riitta Kokko; Akseli Hemminki; Maija Tarkkanen; Taina Turpeenniemi-Hujanen; Sirkku Jyrkkiö; Martti Flander; Leena Helle; Seija Ingalsuo; Kaisu Johansson; Anna-Stina Jääskeläinen; Marjo Pajunen; Mervi Rauhala; Jaana Kaleva-Kerola; Tapio Salminen; Mika Leinonen; Inkeri Elomaa; Jorma Isola Journal: N Engl J Med Date: 2006-02-23 Impact factor: 91.245
Authors: Katrina F Trivers; Mary Jo Lund; Peggy L Porter; Jonathan M Liff; Elaine W Flagg; Ralph J Coates; J William Eley Journal: Cancer Causes Control Date: 2009-04-03 Impact factor: 2.506
Authors: Michael Z Gilcrease; Wendy A Woodward; Marlo M Nicolas; Lynda J Corley; Gregory N Fuller; Francisco J Esteva; Susan L Tucker; Thomas A Buchholz Journal: Am J Surg Pathol Date: 2009-05 Impact factor: 6.394
Authors: S Paik; R Hazan; E R Fisher; R E Sass; B Fisher; C Redmond; J Schlessinger; M E Lippman; C R King Journal: J Clin Oncol Date: 1990-01 Impact factor: 44.544
Authors: Jennifer Y Sheng; Cesar A Santa-Maria; Neha Mangini; Haval Norman; Rima Couzi; Raquel Nunes; Mary Wilkinson; Kala Visvanathan; Roisin M Connolly; Evanthia T Roussos Torres; John H Fetting; Deborah K Armstrong; Jessica J Tao; Lisa Jacobs; Jean L Wright; Elissa D Thorner; Christine Hodgdon; Samantha Horn; Antonio C Wolff; Vered Stearns; Karen L Smith Journal: JCO Oncol Pract Date: 2020-06-30
Authors: Angela K Green; Emeline M Aviki; Konstantina Matsoukas; Sujata Patil; Deborah Korenstein; Victoria Blinder Journal: Breast Cancer Res Treat Date: 2018-08-09 Impact factor: 4.872
Authors: Rachel Yung; Roberta M Ray; Joshua Roth; Lisa Johnson; Greg Warnick; Garnet L Anderson; Candyce H Kroenke; Rowan T Chlebowski; Michael S Simon; Chunkit Fung; Kathy Pan; Di Wang; Wendy E Barrington; Kerryn W Reding Journal: Breast Cancer Res Treat Date: 2020-02-15 Impact factor: 4.872
Authors: Ali Johnson; Leanne Shulman; Jennifer Kachajian; Brian L Sprague; Farrah Khan; Ted James; David Cranmer; Peter Young; Ruth Heimann Journal: J Oncol Pract Date: 2016-08-30 Impact factor: 3.840
Authors: Mariana Chavez-MacGregor; Christina A Clarke; Daphne Y Lichtensztajn; Sharon H Giordano Journal: JAMA Oncol Date: 2016-03 Impact factor: 31.777
Authors: Erica T Warner; Karla V Ballman; Carrie Strand; Judy C Boughey; Aman U Buzdar; Lisa A Carey; William M Sikov; Ann H Partridge Journal: Breast Cancer Res Treat Date: 2016-07-22 Impact factor: 4.872
Authors: Danielle K DePeralta; Takuya Ogami; Jun-Min Zhou; Michael J Schell; Benjamin D Powers; Pamela J Hodul; Mokenge P Malafa; Jason B Fleming Journal: HPB (Oxford) Date: 2019-09-25 Impact factor: 3.647